ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Because of quality control issues, the Sanofi spinoff EuroAPI will halt output of all active pharmaceutical ingredients (APIs) at its plant in Brindisi, Italy. The site produces 11 APIs and intermediates, most of which are anti-infectives such as spiramycin, rifaximin, rifampicin, and teicoplanin. Amid growing competition, EuroAPI announced earlier this year that it will stop making 13 money-losing APIs and close some European sites.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter